



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2022 #2

January 14, 2022

## INSIDE:

Congressional Members Ask FDA to Reevaluate MSM Deferral Policy.....	2
FDA Updates CCP Guidance .....	3
FDA Publishes Updated Information for Blood Establishments Regarding the COVID-19 Pandemic and Blood Donation .....	3
Blood Community Updates Joint Statement .....	4
ASH Promotes Blood Donation in Video .....	4
25 <sup>th</sup> Annual Awards of Excellence Winners.....	5
ABC Members Asked to Complete Annual Collection Survey .....	5
Register for the 60 <sup>th</sup> ABC Annual Meeting .....	5
MEMBER NEWS .....	6
GLOBAL NEWS.....	6
COMPANY NEWS .....	7
CALENDAR .....	8
POSITIONS.....	8

## U.S. Supreme Court Rules on OSHA Vaccine Mandate

A ruling from the U.S. Supreme Court this week blocked implementation of the Occupational Safety and Health Administration (OSHA) vaccine and testing mandates for companies with 100 employees or more. According to the Court, while Congress did provide OSHA with the power to regulate occupational dangers — it did not extend to broader public health.

Thus, blood centers with 100 or more employees are not required to comply with the OSHA Emergency Temporary Standard that would have required employees either be vaccinated or tested weekly and wear masks.

U.S. Labor Secretary Marty Walsh issued a statement following the decision of the court. “The emergency temporary standard is based on science and data that show the effectiveness of vaccines against the spread of coronavirus and the grave danger faced by unvaccinated workers... We urge all employers to require workers to get vaccinated or tested weekly to most effectively fight this deadly virus in the workplace. Employers are responsible for the safety of their workers on the job, and OSHA has comprehensive COVID-19 [guidance](#) to help them uphold their obligation. Regardless of the ultimate outcome of these proceedings, OSHA will do everything in its existing authority to hold businesses accountable for protecting workers, including under the COVID-19 National Emphasis [Program](#) and General Duty [Clause](#).”

The Supreme Court did uphold the Centers for Medicaid and Medicare Services' vaccination mandate that applies to healthcare facilities that bill to Medicaid and Medicare. Please contact America's Blood Centers Senior Director of Federal Government Affairs [Diane Calmus, JD](#) with any questions.

(Source: MCN 22-010, 1/13/22) 💧



## Congressional Members Ask FDA to Reevaluate MSM Deferral Policy

Members of the U.S. [House of Representatives](#) and [Senate](#) sent separate letters to the U.S. Food and Drug Administration (FDA) “urging the agency to reassess its recommended three-month blanket deferral period for men who have sex with men (MSM). In a news release from Chair of the House Committee on Oversight and Reform Rep. Carolyn B. Maloney (D-N.Y.) which included the endorsement of Reps. Jamie Raskin (D-Md.), Alexandra Ocasio-Cortez (D-N.Y.), and Rep. Katie Porter (D-Calif.), the House members described the current blood donation deferral criteria for MSM as having a “discriminatory effect of preventing gay and bisexual men from safely donating blood amid a national blood shortage.”

While acknowledging that the FDA had taken steps in the “right direction” in revising the deferral criteria in 2020, the Representatives stated in their letter that additional change is needed. “While FDA’s 2020 revision was a step in the right direction, the three-month deferral period continues to prevent gay and bisexual men from safely donating blood. Since FDA last updated its blood donation recommendations, other countries have moved in the direction of individual risk-based assessment for potential donors...In light of the urgent crisis facing America’s blood supply, we urge FDA to take immediate action to reassess the existing three-month blanket deferral period for gay and bisexual men so that every person who can safely donate blood in the United States has the opportunity to do so.”

The House letter concluded by asking the FDA to provide an update to the committee on both the current deferral policy and any future modification plans.

The Senate letter went to U.S. Department of Health and Human Services Secretary Xavier Becerra, JD. It stated that, the current FDA policy is “decreasing the eligible donor base and depriving patients of needed blood...[and] unnecessarily stigmatizes and harms the LGBTQ+ community. The broad consensus among the medical community indicates that the current scientific evidence does not support these discriminatory restrictions, and that a policy focused on individual risk assessment rather than an effective ban on gay and bisexual men would be far more appropriate.” The letter included signatures from Sens. Tammy Baldwin (D-Wisc.), Elizabeth Warren (D-Mass.), Ed Markey (D-Mass.), Bob Casey (D-Penn.), Tammy Duckworth (D-Ill.), Richard Blumenthal (D-Conn.), Sherrod Brown (D-Ohio), Bernie Sanders (I-Vt.), Chris Coons (D-Del.), Mazie Hirono (D-Hawaii), Maria Cantwell (D-Wash.), Angus King (I-Maine), Cory Booker (D-N.J.), Catherine Cortez Masto (D-Nev.), Patrick Leahy (D-Vt.), Amy Klobuchar (D-Minn.), Ron Wyden (D-Oreg.), Jeff Merkley (D-Oreg.), Michael Bennet (D-Colo.), Tina Smith (D-Minn.), Martin Heinrich (D-N. Mex.), and Alex Padilla (D-Calif.).

(Source: Rep. Carolyn Maloney [News Release](#), 1/13/21; Sen Tammy Baldwin [News Release](#), 1/13/21) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry  
Chief Medical Officer: Rita Reik  
Editor: Mack Benton  
Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to  
[memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
America’s Blood Centers  
1717 K St. NW, Suite 900, Washington, DC 20006  
Phone: (202) 393-5725  
Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).

## FDA Updates CCP Guidance

The U.S. Food and Drug Administration (FDA) updated its “[Investigational COVID-19 Convalescent Plasma Guidance for Industry](#)” to incorporate changes associated with the recently revised Emergency Use Authorization (EUA) Letter of Authorization for convalescent plasma (CCP).

The new guidance supersedes the guidance of the same title issued on February 11, 2021. Minor changes have been made to the donor qualifications listed in the previous guidance. CCP is to be collected only from individuals who meet the following qualifications:

- “[i]ndividuals who had symptoms of COVID-19 and a documented positive diagnostic result, with complete resolution of symptoms at least 10 days prior to donation; or
- [i]ndividuals who were never symptomatic, never had a positive diagnostic result, but are tested with two different tests to detect SARS-CoV-2 antibodies (the EUA lists the authorized tests and qualifying titer levels).”

The updated guidance does not detail an enforcement discretion period for implementation. Existing CCP inventory may be used, if the units were qualified with an authorized test and meet the titer requirements outlined in the revised EUA. ABC will continue to review the document and provide updates to member blood centers. Please contact ABC Director of Regulatory Affairs [Jill Evans](#) with questions.

**CCP FAQs.** To assist member blood centers with the evolving CCP guidance, ABC has put together a [FAQ sheet to be shared with your teams](#). The FAQs address FDA’s recent updates to its [Investigational COVID-19 Convalescent Plasma Guidance for Industry](#) and the Emergency Use Authorization (EUA) Letter of Authorization for convalescent plasma (CCP). ABC has also updated its position [statement](#) on CCP.

(Source: FDA CCP [Guidance](#), 1/7/21) 💧

## FDA Publishes Updated Information for Blood Establishments Regarding the COVID-19 Pandemic and Blood Donation

The FDA issued an “[Updated Information for Blood Establishments Regarding the COVID-19 Pandemic and Blood Donation](#)” and continues to emphasize that it is imperative that healthy individuals continue to donate blood and blood components, including Source Plasma.

The update includes reduced waiting periods after COVID-19 diagnosis or positive COVID-19 testing:

- “[i]ndividuals diagnosed with or suspected of having COVID-19, and who had symptomatic disease, should refrain from donating blood for at least 10 days after complete resolution of symptoms;
- [i]ndividuals who had a positive diagnostic test for SARS-CoV-2 (e.g., nasopharyngeal swab), but never developed symptoms, should refrain from donating at least 10 days after the date of the positive test; [and]
- [i]ndividuals who are tested and found positive for SARS-CoV-2 antibodies, but who did not have prior diagnostic testing and never developed symptoms, can donate without a waiting period and without performing a diagnostic test (e.g., nasopharyngeal swab).”

The eligibility status for vaccinated donors remains the same:

- “[i]ndividuals who received a nonreplicating, inactivated or mRNA-based COVID-19 vaccine can donate blood without a waiting period;
- [i]ndividuals who received a live-attenuated viral COVID-19 vaccine, should wait 14 days before donating; [and]

(continued on page 4)



### FDA Information Update for Blood Establishments (continued from page 3)

- [i]ndividuals who are uncertain about which vaccine they received should wait 14 days before donating, if it is possible they received a live-attenuated viral vaccine.”

(Source: FDA [Announcement](#), 1/12/22) 💧

### **Blood Community Updates Joint Statement**

America’s Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross [issued](#) a joint statement on January 10<sup>th</sup> urging eligible individuals to donate blood during National Blood Donor Month (NBDM) and throughout the winter months. The organizations explained that “blood centers across the country have reported less than a one-day’s supply of blood of certain critical blood types...[and] continue to face a decline in donor turnout, blood drive cancellations, staffing challenges, and donor eligibility misinformation. Yet the need for blood remains constant.”

The statement “urge[d] eligible, healthy individuals to contact their local blood center and make an appointment to donate blood today. We also ask local businesses to encourage their employees, including those working remotely, to find their local blood donation center and schedule an appointment to donate throughout 2022. Doing so is essential to maintaining the stability of the nation’s blood supply, which ensures life-saving medical treatments are available for patients...Blood donation remains a safe way that eligible individuals can help save lives throughout the year...The blood community appreciates the patience of blood donors and blood drive hosts during this tumultuous time for our nation. If a donation appointment is not immediately available or a blood drive is moved for various scheduling reasons, please schedule for the next appointment; the need for blood continues to be significant as the pandemic persists.”

A PDF version of the full statement is [available](#) on the ABC public website.

(Source: Joint [Statement](#), 1/10/22) 💧

### **ASH Promotes Blood Donation in Video**

U.S. Assistant Secretary for Health Admiral Rachel Levine, MD [tweeted](#) a video on January 10<sup>th</sup> promoting blood donation during National Blood Donor Month (NBDM). In the tweet, Admiral Levine states, “January is #NationalBloodDonorMonth! Due to our nation’s blood supply being critically low, blood donors are needed everywhere. If you are eligible, you can help save a life by donating blood. Visit a blood donation center near you today!”

(Source: Admiral Levine [Tweet](#), 1/10/22) 💧





**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### 25<sup>th</sup> Annual Awards of Excellence Winners

Recipients of America's Blood Centers' (ABC) 25<sup>th</sup> Annual Awards of Excellence will be honored during an awards ceremony on Tuesday, March 8<sup>th</sup> during the 60<sup>th</sup> ABC Annual Meeting. ABC and its member blood centers will recognize individuals and organizations that have made outstanding contributions in promoting blood donation and improving transfusion medicine. This year's recipients include:

- **William Coenen President's Award** – *Richard Gammon, MD (OneBlood), Brian Gannon (Gulf Coast Regional Blood Center), ABC Staff, and Greg Bishop, Bill Block, Marie DeQuattro, Lynne Elderkin, Jennifer Kapral, and Sam Keith (Blood Centers of America, Inc.)*
- **Thomas F. Zuck Lifetime Achievement Award** – *Michael P. Busch, MD, PhD (Vitalant)*
- **Blood Community Advocate of the Year** – *Mary J. Homer, PhD*
- **National Partner of the Year** – *Facebook and Microsoft*
- **Corporation of the Year Award** – *Broken Yolk Cafe (San Diego Blood Bank)*
- **Larry Frederick Award** – *City of La Quinta Mayor Linda Evans (LifeStream Blood Bank)*
- **ABC Outstanding Blood Drive of the Year** – *Cincinnati Arts Associations (Hoxworth Blood Center)*
- **ABC Outstanding Public Relations Campaign** – *COVID Rescue Team (Vitalant)*

Thank you to all blood centers that submitted nominations.

(Source: MCN 22-003, 1/7/22) ♦

### ABC Members Asked to Complete Annual Collection Survey

The America's Blood Centers (ABC) Annual Collection Survey for calendar year 2021 has been distributed. ABC member blood centers are asked to complete the survey by January 28<sup>th</sup>. A link to the survey and a copy of the survey questions are available in MCN 22-001. Please contact [Member Services](#) with any questions.

### Register for the 60<sup>th</sup> ABC Annual Meeting

[Register](#) today for the [60<sup>th</sup> ABC Annual Meeting](#) and 25<sup>th</sup> Annual Awards of Excellence. These events will take place March 7<sup>th</sup>-9<sup>th</sup>, 2022 at the Ritz-Carlton (Pentagon City) in Arlington, Va. Please secure your hotel [reservation](#) today. This year's meeting will be in-person while [Advocacy Day](#) will be held virtually the following week given continued visitor restrictions on Capitol Hill. This will allow each blood center to bring together multiple colleagues to connect with their members of Congress and their staff. More information will be provided to ABC members as it becomes available. The ABC Annual Meeting brings together blood center executives and national leaders to discuss advocacy and regulatory updates, the latest in science, medicine, and technical affairs, and hot topics facing the blood community. In addition, ABC is excited to share that the final day of this year's meeting will feature two in-depth training workshops focused on building tangible advocacy skills that can immediately benefit your center. The program-at-a-glance is [available](#). Please contact [ABC Member Services](#) with questions. ♦





## MEMBER NEWS

**Vitalant** and St. Mary's Hospital and Medical Center have signed a letter of intent "to transition blood collection operations to Vitalant." A joint news release from the organizations also stated that "The St. Mary's Blood Donor Center at the Pavilion (Grand Junction, Colo.) will continue to collect and provide blood products during the transition to Vitalant, which is expected to be complete by the summer of 2022." Bryan Johnson, president of St. Mary's Hospital and Medical Center, stated in the news release, "[o]ver the years, operational requirements implemented by the Food and Drug Administration (FDA) have increased the complexity of operating a blood donor center within a hospital. Utilizing the expertise of a blood collection organization that has a sole focus on blood supply and donor management makes the most effective and efficient use of the community blood supply. It also allows us to further focus on our specialty and passion—patient care."

(Source: Vitalant and St. Mary's Hospital and Medical Center [Joint News Release](#), 1/12/22)

**ImpactLife** held a news conference this week to [announce](#) that the organization has joined the Blood Emergency Readiness Corps (BERC). "In the COVID-19 pandemic, blood centers have seen greater uncertainty and scarcity in the blood supply," said Mike Rasso, director of Sales and Inventory at ImpactLife, in the news release. "While we have worked to avoid blood shortages in our region, we know the demand for blood can spike at any time. Joining BERC gives us confidence that sources are readily available for specific situations as defined by the BERC program."

(Source: ImpactLife [News Release](#), 1/10/22) 💧

## GLOBAL NEWS

**France is planning to [revise](#) its blood donation deferral criteria for men who have sex with other men (MSM). French Health Minister Olivier Véran announced that the changes which will take effect March 16<sup>th</sup> according to *Le Parisien*. During a press briefing to address the policy revisions, Director General of Health Jérôme Salomon stated "[there will] no longer [be] any reference to sexual orientation" in the questions asked of individuals prior to donating. Minister of Health Véran added, "[w]e are ending an inequality that was no longer justified."**

(Source: *Le Parisien*, [Blood donation open to homosexuals without conditions from March](#), 1/11/22)

**This week, Greece also [announced](#) that an upcoming change to its deferral policies for MSM is forthcoming.** Health officials signed a decree that removes a lifetime deferral for MSM, according to a report from *Greek City Times*. The revised policy is set to take effect following its publication in the country's *Government Gazette*. The [decree](#) states, "[for] the first time in the new form, sexual orientation is disconnected from the criteria that must be met by prospective blood donors. This is a commitment of the Minister of Health Thanos Plevris from the first days he took office, which became a reality. It is recalled that the form of the National Blood Donation Center, included the provision that [individuals] cannot become a voluntary blood donor, who had entered into even one homosexual relationship since 1977."

(Source: *Greek City Times*, [Ban on gay or bisexual men giving blood donations lifted in Greece](#), 1/12/22)

**The World Health Organization (WHO) published an interim [statement](#) on "COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC).** In the statement, the TAG-CO-VAC explained that "the composition of current COVID-19 vaccines may need to be updated, to ensure that COVID-19 vaccines continue to provide WHO-recommended [levels](#) of protection against infection and

(continued on page 7)



## GLOBAL NEWS (continued from page 6)

disease by variants of concern (VOCs), including Omicron and future variants.” The advisory group added that potential changes to the composition of the current available vaccines is:

- “to ensure that vaccines continue to meet the criteria established in WHO’s Target Product Profile for COVID-19 vaccines, including protection against severe disease; [and]
- to improve vaccine-induced protection.”

(Source: WHO [Interim Statement](#), 1/11/22) 💧

### Upcoming ABC Webinars – Don’t Miss Out!

- **Paid Donors-Platelet and Cellular Therapy Blood Center Perspectives Webinar** – February 15<sup>th</sup> from 3-4:30 PM ET. More information coming soon.
- **SMT Journal Club Webinar** – March 29<sup>th</sup> from 3-4 PM ET. More information coming soon.

## COMPANY NEWS

**BioMarin Pharmaceutical Inc.** [reported](#) “positive results” from an ongoing phase III clinical trial with 134 participants of its investigational gene therapy to treat severe hemophilia in adults. According to the news release, “annualized bleeding rate (ABR) was significantly reduced by 4.1 treated bleeds per year (p-value <0.0001), or 85 percent from a baseline mean of 4.8 (median 2.8), in the pre-specified primary analysis in participants from a prior non-interventional study (rollover population; N=112; median follow-up of 110 weeks). The mean ABR was 0.8 (median 0.0) through the entire efficacy evaluation period, 0.9 (median 0.0) during year one, and 0.7 (median 0.0) during year two.” The analysis also found that the gene therapy “also significantly reduced the mean annualized Factor VIII infusion rate in the rollover population by 133 infusions per year (p-value <0.0001) or 98 percent from baseline. The mean annualized infusion rate was 2.6 (median 0.0) through the entire efficacy evaluation period, 1.5 (median 0.0) during year one, and 3.4 (median 0.0) during year two.” The news release noted that the therapy “continue[s] to be well tolerated...No participants developed inhibitors to Factor VIII, malignancy, or thromboembolic events. During year two, no new safety signals emerged, and no treatment-related serious adverse events (SAE) were reported.”

(Source: BioMarin Pharmaceutical Inc. [News Release](#), 1/9/22)

**Blood Bank Computer Systems, Inc. (BBCS)** [issued](#) a news release announcing a collaboration with ABC member LifeSouth Community Blood Centers to develop a blood establishment computer system (BECS). The system, BBCS Next Generation, will be available and sold by BBCS to blood centers worldwide upon completion and will be designed to improve the company’s existing BECS “with a cloud first approach while making many advancements targeted in helping blood centers meet their collection goals.” Kim Kinsell, JD, president and chief executive officer at LifeSouth, added in the news release, “BBCS has a proven track record of success with providing high quality, reliable software for community blood centers. We believe our combined years of experience in the development and maintenance of BECS systems will help us collaboratively develop a robust, dependable and modern NextGen platform for the entire blood banking industry.”

(Source: BBCS [News Release](#), 1/7/22)

(continued on page 8)

## COMPANY NEWS (continued from page 7)

**Editas Medicine, Inc.** [announced](#) that the U.S. Food and Drug Administration (FDA) “has cleared” the investigational new drug application (IND) for its investigational gene therapy to treat transfusion-dependent beta thalassemia (TDT). The company now plans to begin a phase I/II clinical trial this year “to assess the safety, tolerability, and preliminary efficacy” of the therapy which uses “CRISPR/Cas12a gene editing technology to precisely make a DNA change that restores production of fetal hemoglobin (HbF).” The company describes the investigational therapy as a “transformative, one-time treatment for people living with severe sickle cell disease (SCD) or TDT.”

(Source: Editas Medicine, Inc. [News Release](#), 12/20/21) ♦

## CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

### 2022

Mar. 7-9. **ABC Annual Meeting, Washington, D.C.** [Registration](#) is open. More information available [here](#).

Mar. 15-16. **International Plasma and Fractionation Association (IPFA) and the European Blood Alliance (EBA) Symposium on Plasma Collection and Supply, Amsterdam, the Netherlands.** Registration is [open](#). More information available [here](#).

Mar. 16. **ABC Advocacy Day (Virtual).** Registration is [open](#). More information available [here](#).

April 5-7. **ABC Technical and Quality Workshop, Louisville, Ky.** More information available [here](#).

April 12-13. **17<sup>th</sup> Annual FDA and the Changing Paradigm for HCT/P Regulation, Cambridge Md.** Registration is [open](#). More information available [here](#).

May 10-12. **2022 ADRP Conference, Phoenix, Ariz.** [Registration](#) is open.

June 4-8. **37<sup>th</sup> Annual International Congress of ISBT, Kuala Lumpur, Malaysia.** Additional details coming [soon](#). ♦

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Supervisor of Component Production (Carter BloodCare).** Principal Accountability: Assists in all aspects of the coordination, management, and supervision of Component Production manufacturing functions. The position will oversee daily operations, participate in interviews for staff vacancies, and directly supervise the Production Coordinators and Production Technicians. This includes solving personnel problems, addressing procedural or behavioral problems, and making verbal or written reports to management. This job requires the ability to make sound judgments of overall production and quality with

the strictest adherence to regulations set forth by, but not limited to FDA, AABB, EU, OSHA, CLIA, and DOT. The position will develop staff and hold them accountable to Carter BloodCare core values. The position must have flexibility to respond to emergency, disaster, or weather situations with little or no notice. Education: High School Graduate. Experience: Two years’ supervisory experience in a blood banking industry with emphasis on component production or five years in a supervisory position in a government regulated production

(continued on page 9)



**POSITIONS** (continued from page 8)

environment. Six months' experience in blood banking, regulated production, or regulated laboratory required. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search job # 31659.

**Medical Technologist 1 - MT / MLS (Carter BloodCare).** Principal Accountability. The Medical Technologist 1 (MT 1) will report to the Manager or designee of Reference & Transfusion (R&T) Services in Bedford, Texas. The incumbent will participate in all activities in the R&T Services to include but not limited to: 1. Support Carter BloodCare's (CBC) vision, mission, and core values. 2. Maintain compliance with the Carter BloodCare's (CBC) attendance policies and department schedules as outlined in the CBC Employee Handbook. 3. Perform testing and services associated with assigned departmental duties. These duties are in the scope of complexity according to accrediting agencies. 4. Participation in competency, proficiency, and educational opportunities. Education: Bachelor's degree required. Medical Technologist: MT (ASCP), BB (ASCP), MT (AMT) or equivalent certification required. Experience: Recent graduate from an accredited Clinical Laboratory Sciences (CLS) program within the last five years and currently board eligible. NOTE: Must successfully obtain, maintain board certification (i.e., MLS (ASCP) or equivalent) and provide board certification documentation to the CBC Human Resources department within 12 months of hire date. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search Req # 29048 or 28777.

**Clinical Apheresis Manager (Carter BloodCare).** Principal Accountability: The Manager of Clinical Apheresis Services is responsible for meeting Carter BloodCare and departmental objectives. The Manager is responsible for ensuring excellent customer service and managing issues. The Manager provides oversight for a team of nurses and apheresis collection technicians who perform therapeutic procedures on hospitalized patients for treatment of disease, or collection of cells from donor or patient peripheral blood for various cell therapy treatments or research projects. The Manager is responsible for managing daily operations, business activities, and quality patient care. The position is responsible for staffing field assignments and performing procedures in the field to assist in training or as staffing indicates. Also, the Manager is responsible for maintaining statistics and quality indicators of procedures and records of preventative or responsive maintenance along with quality control of supplies and equipment. Regular full-time attendance is required during office hours. Education: Bachelor of Science in Nursing. RN active licensure in the State of Texas, preferably with Hemapheresis Practitioner (HP) or Qualification in Apheresis (QIA) credentialing. Experience: At least five years' apheresis experience of which

three years should be in therapeutic/PBSC apheresis. Two years' management experience required. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search Req # 27905.

**Assistant Manager of Hematology Services (Blood Center Quality Control) (Carter BloodCare).** Principal Accountability. Carter BloodCare is hiring for a Hematology Assistant Manager (Blood Center Quality Control). This position is responsible for detailed record keeping of quality control testing, reporting quality control results to medical directors, the technical review of quality control documents, and scheduling/timekeeping. In addition to direct oversight of the department staff, this role will also oversee the training of lab staff for technical processes. The Assistant Manager will be responsible for all daily, routine departmental activities and operations, consulting the Manager of Hematology Services as needed. The individual will oversee strict fiscal adherence to the budget and other administrative activities for the department as assigned by the Manager or Medical Director. The Assistant Manager is able and willing to perform any departmental task as needed to ensure efficient workflow in the department. Regular full-time attendance is required during office hours. Education: Minimum MT ASCP or equivalent required. Experience: Minimum four years of laboratory experience required. Minimum two years of supervisory experience required. Previous management experience preferred. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search job # 31586.

**Compatibility Testing Lab Supervisor – (2<sup>nd</sup> shift) Tallahassee, FL – Recruitment Bonus Eligible!** Bachelor's degree in medical technology, biological science, or related field and three plus years in a clinical laboratory, preferably in blood banking. Requires a current Florida Technologist license in Immunohematology or Blood Banking; FL Supervisor License preferred. OneBlood offers competitive benefits, including **excellent** shift differential pay for night and weekend schedules, Paid Time Off, Student Loan Repayment Program, a **FREE** medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at [www.oneblood.org/careers](http://www.oneblood.org/careers).

**Medical Technologist – Various locations available in Florida.** A valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking is required. Prior blood banking experience preferred. Multiple shifts available. OneBlood offers competitive benefits, including **excellent** shift differential pay for night and weekend schedules, Paid Time Off,

(continued on page 10)

**POSITIONS** (continued from page 9)

Student Loan Repayment Program, a **FREE** medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at [www.oneblood.org/careers](http://www.oneblood.org/careers).

**Registered Nurse – opportunities in Ft. Lauderdale, Jacksonville, St. Petersburg and Orlando. Recruitment Bonus eligible!** Current and valid Florida RN license, current BLS CPR certification, and a valid and clear driver's license is required. Flexibility in scheduling needed to meet the needs of the department; travel required. OneBlood offers competitive benefits, including **excellent** shift differential pay for night and weekend schedules, Paid Time Off, Student Loan Repayment Program, a **FREE** medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at [www.oneblood.org/careers](http://www.oneblood.org/careers).

**QRA Supervisor (Req#: R219667).** Reporting to the Regulatory & Accreditation Compliance Director, the QRA Supervisor is responsible for carrying out day-to-day activities at the Stanford Blood Center Quality & Regulatory Affairs department by appropriate management of the QRA Specialist, ensure timely review of records and completion of QRA activities. Assume the responsibility SBC safety initiatives, disaster preparedness, and support continuity of operation across the organization. Responsibilities: Quality Assurance/Training/ GMP/GTP/GLP: Lead the department's quality activities, initiatives, and process improvement activities. Perform training on QRA core functions and activities, Good Manufacturing Practice/Good Tissue Practice/Good Laboratory Practice, and safety. Compliance: Ensure compliance to current regulations and accreditation requirements by federal, state, county, and accreditation agencies. Team Leadership: Manage the performance of direct reports. Set team objectives, priorities, and resources to align staff with Blood Center objectives. Responsible for interviewing, hiring, training, coaching, performance management, and performance reviews of direct reports. Safety: Lead the safety, emergency, and disaster management. Quality Management System: Provide oversight on the appropriate use of the quality management tools in handling the various documents, records, and activities of the blood center. Qualifications: Bachelor's Degree Required. One to two years supervisory experience in a regulated or GMP (Good Manufacturing Practice) required. Click [here](#) to apply.

**Therapeutic Apheresis Nurse.** LifeSouth Community Blood Centers is currently seeking an experienced professional to join our team as a Therapeutic Apheresis Nurse in **Jacksonville, FL**. This position is responsible for traveling to hospitals to perform apheresis procedures.

Nurses will only care for one patient at a time and will work alongside hospital nurses and physicians to complete procedures. Nurses will also spend time at the LifeSouth office to coordinate upcoming apheresis procedures and organize necessary documentation. Training: Don't let a lack of apheresis experience stop you from applying! No previous apheresis experience is required. If hired, you will be given sufficient on-the-job training to learn the specialized skills this position requires. Training for this position will be conducted during regular business hours. This is a full-time position. Starting salary range is \$60,000 - \$66,000 annually plus travel and on-call bonus. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. Applicants should apply here: <https://lifesouth.csod.com/ux/ats/career-site/5/home/requisition/2490?c=lifesouth>

**Therapeutic Apheresis Nurse.** LifeSouth Community Blood Centers is currently seeking an experienced professional to join our team as a Therapeutic Apheresis Nurse in **Gainesville, FL**. This position is responsible for traveling to hospitals to perform apheresis procedures. Nurses will only care for one patient at a time and will work alongside hospital nurses and physicians to complete procedures. Nurses will also spend time at the LifeSouth office to coordinate upcoming apheresis procedures and organize necessary documentation. Training: Don't let a lack of apheresis experience stop you from applying! No previous apheresis experience is required. If hired, you will be given sufficient on-the-job training to learn the specialized skills this position requires. Training for this position will be conducted during regular business hours. This is a full-time position. Starting salary range is \$60,000 - \$66,000 annually plus travel and on-call bonus. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. Applicants should apply here: <https://lifesouth.csod.com/ux/ats/career-site/5/home/requisition/2489?c=lifesouth>

**Clinical Lab Scientist 1.** The College of Medicine, Hoxworth Blood Center is recruiting a Clinical Laboratory Scientist 1 in the Quality Control Laboratory. This position will support the University's mission and commitment to excellence and diversity in our students, faculty, staff, and all our activities. Clinical Laboratory Scientist 1 will perform routine and complex quality control testing of blood and blood components, as well as high-level evaluation, review, and interpretation of test results. Candidates shall be able to perform with minimal supervision, be proficient in computerized data entry and retrieval functions, and communicate effectively with individuals within and outside the department. This position will be trained on first shift and assigned to work on the second shift after training is completed. Required Education: Bachelor's Degree in Medical Technology,

(continued on page 11)

POSITIONS (continued from page 10)

Medical Laboratory Sciences, or other related biological science. Four (4) years of relevant work experience and/or other specialized training can be used in lieu of education requirement. Required Trainings/Certifications: Some labs require MLT(ASCP), MLS(ASCP), MT(ASCP), BB(ASCP), or SBB(ASCP). The University of Cincinnati is an Affirmative Action / Equal Opportunity Employer / Minority / Female / Disability / Veteran. Apply today at [Hoxworth Blood Center Hoxworth Blood Center \(uc.edu\)](#). ♦